Burkitt Lymphoma - Pipeline Review, H1 2016

  • ID: 3746936
  • Report
  • 115 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Arvinas, Inc.
  • AstraZeneca Plc
  • Bluebird bio, Inc.
  • Immunomedics, Inc.
  • Seattle Genetics, Inc.
  • MORE
Burkitt Lymphoma - Pipeline Review, H1 2016

Summary

‘Burkitt Lymphoma - Pipeline Review, H1 2016’, provides an overview of the Burkitt Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Burkitt Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burkitt Lymphoma and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Burkitt Lymphoma
- The report reviews pipeline therapeutics for Burkitt Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Burkitt Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Burkitt Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Burkitt Lymphoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Burkitt Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Burkitt Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Arvinas, Inc.
  • AstraZeneca Plc
  • Bluebird bio, Inc.
  • Immunomedics, Inc.
  • Seattle Genetics, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Burkitt Lymphoma Overview

Therapeutics Development

Pipeline Products for Burkitt Lymphoma - Overview

Pipeline Products for Burkitt Lymphoma - Comparative Analysis

Burkitt Lymphoma - Therapeutics under Development by Companies

Burkitt Lymphoma - Therapeutics under Investigation by Universities/Institutes

Burkitt Lymphoma - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Burkitt Lymphoma - Products under Development by Companies

Burkitt Lymphoma - Products under Investigation by Universities/Institutes

Burkitt Lymphoma - Companies Involved in Therapeutics Development

AbbVie Inc.

Arvinas, Inc.

AstraZeneca Plc

Bluebird bio, Inc.

Constellation Pharmaceuticals, Inc.

Immunomedics, Inc.

Karyopharm Therapeutics, Inc.

Millennium Pharmaceuticals, Inc.

Seattle Genetics, Inc.

Takeda Pharmaceutical Company Limited

Theravectys SA

Burkitt Lymphoma - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

19-3s - Drug Profile

Product Description

Mechanism of Action

R&D Progress

20-3s - Drug Profile

Product Description

Mechanism of Action

R&D Progress

alisertib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ARV-825 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AZD-6738 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

bb-2121 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

denintuzumab mafodotin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

E1-3s - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Epstein-Barr virus vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ibrutinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ixazomib citrate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody Conjugate to Target CD20 for Leukemia and Burkitt Lymphoma - Drug Profile

Product Description

Mechanism of Action

R&D Progress

selinexor - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SH-7129 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SH-7133 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SH-7139 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit BET for Cancer - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Burkitt Lymphoma - Recent Pipeline Updates

Burkitt Lymphoma - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Burkitt Lymphoma, H1 2016

Number of Products under Development for Burkitt Lymphoma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Burkitt Lymphoma - Pipeline by AbbVie Inc., H1 2016

Burkitt Lymphoma - Pipeline by Arvinas, Inc., H1 2016

Burkitt Lymphoma - Pipeline by AstraZeneca Plc, H1 2016

Burkitt Lymphoma - Pipeline by Bluebird bio, Inc., H1 2016

Burkitt Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016

Burkitt Lymphoma - Pipeline by Immunomedics, Inc., H1 2016

Burkitt Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016

Burkitt Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016

Burkitt Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016

Burkitt Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016

Burkitt Lymphoma - Pipeline by Theravectys SA, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Burkitt Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016

Burkitt Lymphoma - Dormant Projects, H1 2016

List of Figures

Number of Products under Development for Burkitt Lymphoma, H1 2016

Number of Products under Development for Burkitt Lymphoma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AbbVie Inc.
Arvinas, Inc.
AstraZeneca Plc
Bluebird bio, Inc.
Constellation Pharmaceuticals, Inc.
Immunomedics, Inc.
Karyopharm Therapeutics, Inc.
Millennium Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Takeda Pharmaceutical Company Limited
Theravectys SA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll